<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28072">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02741271</url>
  </required_header>
  <id_info>
    <org_study_id>0887A-087</org_study_id>
    <secondary_id>MK-0887A-087</secondary_id>
    <secondary_id>2009-010110-30</secondary_id>
    <nct_id>NCT02741271</nct_id>
  </id_info>
  <brief_title>Study of Safety and Efficacy of Mometasone Furoate Used in Combination With Formoterol Fumarate Compared With Mometasone Furoate in Children (5 to 11 Years of Age) With Persistent Asthma (MK-0887A-087)</brief_title>
  <official_title>A Phase III, Randomized, Active-controlled, Parallel-group Clinical Trial to Study the Efficacy and Long-term Safety of Mometasone Furoate/Formoterol Fumarate (MF/F, MK-0887A [SCH418131]), Compared With Mometasone Furoate (MF, MK-0887 [SCH032088]), in Children With Persistent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the efficacy and safety of mometasone furoate/formoterol fumarate
      (MF/F) 100/10 mcg to mometasone furoate (MF) 100 mcg, both administered by metered-dose
      inhaler, in 5- to 11-year-old children with persistent asthma. This study will evaluate the
      change in forced expiratory volume in one second (FEV1) from baseline as a measure of
      pulmonary function
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Percent Predicted Morning (AM) Forced Expiratory Volume in 1 Second (FEV1) Analyzed at 60 Minutes Post-dose</measure>
    <time_frame>Baseline (Day 1) and at Weeks 1, 4, 8, and 12 of treatment (up to 12 Weeks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs)</measure>
    <time_frame>From time of first dose of double-blind study drug until the end of follow-up (up to 26 weeks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Discontinuing Study Drug Due to AEs</measure>
    <time_frame>Up to 24 weeks after the first dose of double-blind study drug (up to 24 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percent Predicted AM FEV1 Analyzed Beginning at 4 Hours Post-dose on Day 1 and Continuing to 2 Hours and 60, 30, 15, and 5 Minutes Post-dose</measure>
    <time_frame>Baseline (Day 1) and at Week 12 of treatment (up to 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percent Predicted AM FEV1 Analyzed at 4 Hours Post-dose</measure>
    <time_frame>Baseline (Day 1) and at Week 12 of treatment (up to 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Change From Baseline in Percent Predicted AM Pre-dose FEV1</measure>
    <time_frame>Baseline and at Weeks 4, 8, and 12 of treatment (up to 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Daily albuterol/salbutamol (SABA) Use</measure>
    <time_frame>Baseline and from time of first dose of SABA until 12 weeks of treatment (up to 12 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>MK-0887A 100/10 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During a 2-week run-in period participants will receive 100 mcg mometasone furoate (MK-0887), administered by metered-dose inhaler (MDI) twice daily (BID). After the 2-week run-in period, participants will receive 100/10 mcg mometasone furoate/formoterol fumarate (MK-0887A) administered by MDI twice daily for 24 weeks of the double-blind study period. Participants can use rescue medication as needed for worsening asthma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-0887 100 mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During a 2-week run-in period participants will receive 100 mcg mometasone furoate (MK-0887) administered by MDI twice daily. After the 2-week run-in period, participants will continue to take mometasone furoate by MDI twice daily for 24 weeks of the double-blind study period. Participants can use rescue medication as needed for worsening asthma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-0887A 100/10 mcg</intervention_name>
    <description>mometasone furoate/formoterol fumarate (MF/F) metered-dose inhaler (MDI), 100/10 mcg, oral inhalation</description>
    <arm_group_label>MK-0887A 100/10 mcg</arm_group_label>
    <other_name>DULERA®</other_name>
    <other_name>SCH418131</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-0887 100 mcg</intervention_name>
    <description>mometasone furoate (MF) MDI, 100 mcg, oral inhalation</description>
    <arm_group_label>MK-0887 100 mcg</arm_group_label>
    <other_name>ASMANEX® ASMANEX HFA®</other_name>
    <other_name>SCH032088</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albuterol/Salbutamol</intervention_name>
    <description>Orally inhaled as prescribed and as needed (PRN) as a rescue medication</description>
    <arm_group_label>MK-0887A 100/10 mcg</arm_group_label>
    <arm_group_label>MK-0887 100 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone/Prednisolone</intervention_name>
    <description>Taken orally as prescribed and PRN as a rescue medication</description>
    <arm_group_label>MK-0887A 100/10 mcg</arm_group_label>
    <arm_group_label>MK-0887 100 mcg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has a diagnosis of asthma of ≥ 6-months duration prior to study start

          -  Has asthma that is adequately controlled, according to the clinical judgment of the
             investigator, on a stable dose of inhaled corticosteroid (ICS) combined with
             long-acting beta-agonist (LABA) ≥ 4 weeks prior to study start

          -  Is able to demonstrate at screening, an FEV1 &gt;60% and ≤90% predicted -Is able to
             demonstrate at screening, an increase in absolute FEV1 of at least 12% within 30
             minutes after administration of albuterol/salbutamol.

        Exclusion Criteria:

          -  Requires &gt;8 inhalations per day of albuterol (100 mcg per actuation), and/or &gt;2
             nebulized treatments per day of 2.5 mg albuterol on any 2 consecutive days between
             the screening visit and the study start

          -  Has a clinical worsening of asthma between the screening visit and the study start,
             that results in emergency room visit (for an asthma exacerbation), hospitalization
             due to asthma, or treatment with additional, excluded asthma medication (other than
             SABA).

          -  Has experienced an upper or lower respiratory tract infection within the 4 weeks
             prior to screening

          -  Is considered by the investigator to have unstable asthma at the end of the run-in
             period

          -  Has had &gt; 4 asthma exacerbations (defined as a worsening of asthma requiring systemic
             corticosteroid use and/or ≥ 24-hour stay in an emergency department, urgent care
             center, or hospital) within 1 year of the screening visit

          -  Has had a history of life-threatening asthma, including an asthma episode that
             required intubation and/or was associated with an increase in carbon dioxide levels
             in the blood requiring non-invasive ventilator support
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0107)</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0119)</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0106)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0114)</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0122)</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0109)</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0116)</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55441</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0128)</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0124)</name>
      <address>
        <city>Warrensburg</city>
        <state>Missouri</state>
        <zip>64093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0113)</name>
      <address>
        <city>Corning</city>
        <state>New York</state>
        <zip>14830</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0108)</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0103)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0105)</name>
      <address>
        <city>Boerne</city>
        <state>Texas</state>
        <zip>78006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0117)</name>
      <address>
        <city>Dickinson</city>
        <state>Texas</state>
        <zip>77539</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0125)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0110)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0101)</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0120)</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0115)</name>
      <address>
        <city>Greenfield</city>
        <state>Wisconsin</state>
        <zip>53228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MDS Colombia SAS</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Carvajal</last_name>
      <phone>57 1219109011090</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme</name>
      <address>
        <city>Glostrup</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathan Lassota</last_name>
      <phone>45 44824475</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD CARD</name>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soraya Cedraro</last_name>
      <phone>507-282-7200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Pharma Hungary Kft.</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Szabolcs Barotfi</last_name>
      <phone>36 1 888 5300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Latvija SIA</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin Moeschlin</last_name>
      <phone>+46 (0) 8ý578ý135 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Marques</last_name>
      <phone>52 55254819608</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Romania SRL</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simona Olaru</last_name>
      <phone>38 (044) 393 74 80</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme IDEA, Inc.</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatiana Serebriakova</last_name>
      <phone>74959167100, EXT.366</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD (Pty) LTD South Africa</name>
      <address>
        <city>Midrand</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khanyi Mzolo</last_name>
      <phone>27 11 655 3140</phone>
    </contact>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>Denmark</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Mexico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 9, 2017</lastchanged_date>
  <firstreceived_date>April 13, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Mometasone Furoate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
